Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00141830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).
Study identification
- NCT ID
- NCT00141830
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2005 (Type not available)
- Primary completion
- Oct 19, 2006 (Actual)
- Completion
- Oct 19, 2006 (Actual)
- Last update posted
- Sep 29, 2020
2005 – 2006
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Largo | Florida | 33773 | — |
| Not listed | Palm Harbor | Florida | 34684 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Boise | Idaho | 83702 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Frederick | Maryland | 21702 | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | Charlotte | North Carolina | 28210 | — |
| Not listed | Duncansville | Pennsylvania | 16635-0909 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Dallas | Texas | 75231 | — |
| Not listed | San Antonio | Texas | 78217 | — |
| Not listed | Spokane | Washington | 99204 | — |
| Not listed | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00141830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00141830 live on ClinicalTrials.gov.